Aspirin Significantly Reduces the Severity of the Individual Symptoms of Flushing Associated With Niacin Extended-Release Therapy

被引：0
|
作者：
Lewin, Andrew [1 ]
Kashyap, Moti [2 ]
Jiang, Ping [3 ]
Everhart, Wendy [3 ]
Thakker, Kamlesh [3 ]
机构：
[1] Natl Res Inst, Los Angeles, CA USA
[2] Univ Calif Irvine, Long Beach VA Med Ctr, Irvine, CA USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF CARDIOVASCULAR NURSING | 2012年 / 27卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：373 / 373
页数：1
相关论文
共 50 条
  • [1] Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation
    Cefali, E. A.
    Simmons, P. D.
    Stanek, E. J.
    McGovern, M. E.
    Kissling, C. J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (02) : 78 - 88
  • [2] Flushing and other dermatologic adverse events associated with extended-release niacin therapy
    Guyton, John R.
    Simmons, Phillip D.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2009, 3 (02) : 101 - 108
  • [3] Flushing and the HDL-C response to extended-release niacin
    Taylor, Allen J.
    Stanek, Eric J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (04) : 285 - 288
  • [4] Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients
    Kush, Debra
    Hu, Da-Yi
    Ye, Ping
    Kim, Hyo-Soo
    Chen, Erluo
    Sirah, Waheeda
    Sisk, Christine McCrary
    Paolini, John F.
    Maccubbin, Darbie
    CARDIOLOGY, 2009, 114 (03) : 192 - 198
  • [5] Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease
    Maccubbin, Dorbie
    Koren, Michael J.
    Davidson, Michael
    Gavish, Dov
    Pasternak, Richard C.
    Macdonell, Geraldine
    Mallick, Madhuja
    Sisk, Christine McCrary
    Paolini, John F.
    Mitchel, Yale
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (01): : 74 - 81
  • [6] Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire®:: results from a randomised placebo-controlled clinical trial
    Paolini, J. F.
    Mitchel, Y. B.
    Reyes, R.
    Thompson-Bell, S.
    Yu, Q.
    Lai, E.
    Watson, D. J.
    Norquist, J. M.
    Sisk, C. McCrary
    Bays, H. E.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (06) : 896 - 904
  • [7] Aspirin use does not affect lipid efficacy of niacin extended-release treatment
    Thakkar, R.
    Punzi, H. A.
    Davidson, M. H.
    Krause, S.
    Jiang, P.
    Lovell, C.
    Padley, R. J.
    EUROPEAN HEART JOURNAL, 2009, 30 : 377 - 377
  • [8] Following Stable Therapy with Extended Release Niacin/Laropiprant, Continued Extended Release Niacin/Laropiprant Use Reduced Flushing versus Extended Release Niacin Alone in Dyslipidemic Patients
    Chen, Fabian
    Maccubbin, Darbie
    Anderson, Jennifer Weimer
    Sisk, Christine McCrary
    Kher, Uma
    Olsson, Anders
    Bays, Harold E.
    CIRCULATION, 2011, 124 (21)
  • [9] Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors
    Paolini, John F.
    Bays, Harold E.
    Ballantyne, Christie M.
    Davidson, Michael
    Pasternak, Richard
    Maccubbin, Darbie
    Norquist, Josephine M.
    Lai, Eseng
    Waters, M. Gerard
    Kuznetsova, Olga
    Sisk, Christine McCrary
    Mitchel, Yale B.
    CARDIOLOGY CLINICS, 2008, 26 (04) : 547 - 560
  • [10] Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation
    Cefali, E. A.
    Simmons, P. D.
    Stanek, E. J.
    Shamp, T. R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2006, 44 (12) : 633 - 640
12345